Impact of HLA-B −21 genotype on outcome of AML patients. LFS (A) and OS (B) for patients with an M/x genotype (n = 38) or T/T genotype (n = 42) receiving HDC/IL-2 treatment. Five patients (6%) had a M/M genotype, 33 patients (41%) had an M/T genotype, and 42 patients (53%) had a T/T genotype. LFS (C) and OS (D) for AML patients undergoing transplantation with an M/x (n = 32) or T/T (n = 27) genotype.